Oppenheimer & CO Inc Editas Medicine, Inc. Transaction History

Oppenheimer & CO Inc

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 12, 2021	SELL	$39.27 - $72.94 $343,062 - $637,203	-8,736 Closed	0 $0
Q2 2021 Aug 03, 2021	BUY	$31.29 - $56.64 $79,664 - $144,205	2,546 Added 41.13%	8,736 $495,000
Q1 2021 May 10, 2021	BUY	$39.71 - $90.58 $120,083 - $273,913	3,024 Added 95.51%	6,190 $260,000
Q4 2020 Feb 11, 2021	BUY	$27.07 - $84.35 $85,703 - $267,052	3,166 New	3,166 $222,000
Q4 2018 Jan 29, 2019	SELL	$18.19 - $31.79 $340,353 - $594,822	-18,711 Closed	0 $0
Q3 2018 Oct 26, 2018	BUY	$27.65 - $38.39 $517,359 - $718,315	18,711 New	18,711 $595,000

228

54.7M

425K

306K

Ticker EDIT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,737,200
Market Cap $94.9M
Description
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...

Get notified when there are updates to the investment portfolio of Oppenheimer & CO Inc, based on Form 13F filings with the SEC.

Stay updated on Oppenheimer & CO Inc with notifications on news.